A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Public ClinicalTrials.gov record NCT01006122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy
Study identification
- NCT ID
- NCT01006122
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- PF-03654746 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2009
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- May 8, 2014
2009 – 2010
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85006 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85051 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85712 | — |
| Pfizer Investigational Site | Los Angeles | California | 90048 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | Brandon | Florida | 33511 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33707 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30342 | — |
| Pfizer Investigational Site | Macon | Georgia | 31201 | — |
| Pfizer Investigational Site | Vernon Hills | Illinois | 60061 | — |
| Pfizer Investigational Site | Crestview Hills | Kentucky | 41017 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40217 | — |
| Pfizer Investigational Site | Hattiesburg | Mississippi | 39401 | — |
| Pfizer Investigational Site | Hattiesburg | Mississippi | 39402 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Dublin | Ohio | 43017 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19114 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19139 | — |
| Pfizer Investigational Site | Columbia | South Carolina | 29201 | — |
| Pfizer Investigational Site | Austin | Texas | 78731 | — |
| Pfizer Investigational Site | Houston | Texas | 77063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01006122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01006122 live on ClinicalTrials.gov.